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Aims Surveys on heart failure management suggest under-utilization of life-saving evidence-based
treatment. Evidence-based medicine and clinical guidelines are based on the results of randomized
controlled trials. Therefore, we investigated how patients who fulﬁlled the enrolment criteria of
randomized trials were treated in real life.
Methods and results We selected three large placebo-controlled trials of patients with chronic heart
failure, in which ACE-inhibitors (ACE-Is), b-blockers, and spironolactone proved to be safe and effective.
The major enrolment criteria of trials were identiﬁed and applied to patients enrolled in the Euro Heart
Survey on Heart Failure to identify the proportion of patients eligible for treatment and also treated
appropriately. Of the 10 701 patients who were enrolled in the Euro Heart Survey on Heart Failure,
only a small percentage (13%) would have qualiﬁed for participation in at least one of the selected
trials. Patients who fulﬁlled enrolment criteria of the identiﬁed trials were more likely to be treated
with ACE-Is (83% of SOLVD-eligible patients), b-blockers (54% of MERIT-HF-eligible patients), and
aldosterone antagonists (43% of RALES-eligible patients) than trial-ineligible patients. Almost half of
SOLVD-eligible patients who were treated with ACE-Is received the target dose as recommended
in the guidelines, but only ,10% of MERIT-HF eligible patients who were treated with b-blockers
received the target dose.
Conclusion ACE-Is are widely utilized but given in lower doses than proven effective in clinical trials.
b-Blockers are underused and given in lower doses to patients who fulﬁl the enrolment criteria of
relevant landmark trials.
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Introduction
Chronic heart failure (CHF) is a major health problem with a
high morbidity and mortality.1,2 Over the last two decades,
major advances have occurred in the treatment of heart
failure patients. Randomized clinical trials (RCTs) showed
that ACE-inhibitors (ACE-Is),3–5 b-blockers,6–8 and aldoster-
one antagonists9,10 could reduce morbidity and mortality
in patients with heart failure. Guidelines have been estab-
lished to support physicians in clinical decision-making in
this rapidly evolving ﬁeld.11–14 In these guidelines, RCTs
are accorded the highest level of evidence. However,
although physicians are increasingly encouraged to apply
these guidelines in their practise, it is repeatedly observed
that a considerable proportion of heart failure patients do
not receive evidence-based treatment.15–20
Several factors may explain the reported under-utilization
of evidence-based treatment, such as lack of knowledge,
lack of expertise in the use of such drugs, lack of time,
and economic restraints. Another issue that is often
brought forward is the limited generalizability (external val-
idity) of RCTs as it is emphasized that these trials usually
enrol highly selected patients.21–27 In reality, clinicians
may be right to withhold treatment in patients who do not
fulﬁl the inclusion and exclusion criteria used to select
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patients for RCTs. Information is scarce on whether
evidence-based treatment is offered more often to patients
who match the proﬁle of patients who were enrolled in RCTs
when compared with those who were not.
Therefore, we investigated what proportion of patients
with suspected or known heart failure who enrolled the
Euro Heart Survey on Heart Failure19 was eligible for partici-
pation in the largest placebo-controlled trials of ACE-Is,
b-blockers, and aldosterone antagonists, which demon-
strated the effectiveness and safety of these agents. We
then analysed what proportion of patients met or did
not meet these criteria, and whether they were treated
according to the guidelines.
Methods
Euro Heart Survey on Heart Failure
Between March 2000 and May 2001, 46 788 patients from 115 hospi-
tals in 24 ESC member countries were screened for enrolment in the
Euro Heart Survey on Heart Failure.19,20,28 Brieﬂy, all consecutive
discharges and deaths from general medical, cardiology, or
cardiac surgery wards were screened over a 6-week period.
Patients who fulﬁlled one or more of the following four criteria
were enrolled: (i) a clinical diagnosis of heart failure during the
admission; (ii) a diagnosis of heart failure recorded at any time in
the last 3 years; (iii) administration of a loop diuretic for any
reason other than renal failure in the 24 h before death or dis-
charge; and/or (iv) pharmacological treatment for heart failure or
ventricular dysfunction in the 24 h before death or discharge.
Information about characteristics, diagnosis, and treatment on
10 701 enrolled patients was collected.19,20
Trial selection
To compare patients in the RCTs with those enrolled in the Euro
Heart Survey, we selected the largest placebo-controlled trials in
which ACE-Is, b-blockers, and aldosterone antagonists had been
shown to reduce mortality in patients with CHF. These were SOLVD
(ACE-I), MERIT-HF (b-blocker), and RALES (aldosterone anta-
gonist).4,6,9 In addition, we compiled the tabulated patient charac-
teristics, as presented in the main results papers of these trials
(‘pooled RCTs’). Data were pooled if certain characteristics were
available in at least two trials, either by reports of the actual
counts or by percentages.
The major enrolment criteria for these trials were extracted from
the main articles and summarized in Table 1. The most important
inclusion criterion in these trials was the left ventricular ejection
fraction (LVEF). Important exclusion criteria were renal failure,
respiratory diseases (including asthma and chronic obstructive
respiratory disease during the index admission), obstructive valvular
heart disease, acute coronary syndrome during the index admission,
and limited life expectancy by other diseases. Furthermore, we
identiﬁed pacemakers, ventricular assist devices, planned heart
transplantation, congenital heart disease, laboratory values (i.e.
creatinine and potassium), and administered cardiovascular drugs
(i.e. calcium antagonists and amiodarone) as exclusion criteria in
some of these trials.
Identifying trial-eligible survey patients
On the basis of the earlier mentioned criteria, survey patients with
identiﬁable contraindications (i.e. age, co-morbidity, etc.) or a
higher LVEF than allowed in the RCTs were classiﬁed as trial-
ineligible patients. Trial-eligible patients were those who had no
contraindications and fulﬁlled the LVEF criterion, whereas the
remaining patients were classiﬁed as ‘other survey patients’. In
these patients, no quantitative measurement of the LVEF was avail-
able and no contraindications were observed. It should be noted,
however, that deﬁning patients from clinical practise as trial eligible
or trial ineligible is, by necessity, crude.
Within the subgroups of SOLVD-, MERIT-HF-, and RALES-eligible
patients, we analysed the administered dose of ACE-Is and
b-blockers on the day of discharge or the day before death when
compared with the target dose. We deﬁned the target dose as the
minimum recommended maintenance dose or higher approved for
the treatment of heart failure in Europe.13 For ACE-Is, this is
75 mg for captopril, 20 mg for enalapril, 5 mg for ramipril, 5 mg for
lisinopril, and 4 mg for perindopril. For b-blockers, dosages were
150 mg for metoprolol, 50 mg for atenolol, 50 mg for carvedilol,
and 10 mg for bisoprolol.
Statistical analysis
Descriptive statistics included percentages for dichotomous vari-
ables and medians with corresponding 25th and 75th percentiles
Table 1 Major inclusion and exclusion criteria of selected trials
SOLVD 1991 MERIT-HF 1999 RALES 1999
Drug comparison Enalapril Metoprolol Spironolactone
Number of participants 2569 3991 1663
Major enrolment criteria
Age 80 40–80 —
NYHA — II–IV III–IV
LVEF 0.35 0.40 0.35
Renal failure (creatinine level) Exclude (.2.0 mg/dl) — Exclude (.2.5 mg/dl)
Severe pulmonary disease Exclude Exclude —
Severe valve disease Exclude — Exclude
ACS (recent) Exclude Exclude Exclude
Limited life-expectancy Exclude Exclude Exclude
ACE-I therapy Exclude Mandatory Mandatory
b-Blocker therapy — Exclude —
Calcium antagonists — Exclude —
Diuretics Mandatory Mandatorya
Amiodarone — Exclude —
NYHA, New York Heart Association; ACS, acute coronary syndrome.
aPotassium-sparing diuretics excluded.
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for continuous variables. Differences between trial-eligible and
trial-ineligible patients were analysed by x2 and Mann–Whitney
U-test or Kruskal–Wallis test as appropriate. For all tests, a
P-value of ,0.05 (two-sided) was considered statistically signiﬁ-
cant. All analyses were performed with SPSS statistical software
version 12.0.
We acknowledge the fact that patients who died during the initial
hospitalization could have a worse clinical proﬁle and consequently
inﬂuence the results. Therefore, we repeated the analyses exclud-
ing patients who did not survive to hospital discharge. As the
results of the analyses with and without patients who died during
the initial hospitalization were highly consistent, we report our
original choice on the basis of the total survey population.
Results
As shown in Figure 1, only small proportions of patients
enrolled in the Euro Heart Survey on Heart Failure would
have qualiﬁed for participating in the SOLVD (9%), MERIT-
HF (5%), and RALES (7%) trials. Exclusion criteria such as
age and identiﬁed contraindications were the most import-
ant reasons for not classifying patients as trial-eligible. In
addition to this, we were unable to classify a considerable
proportion of patients as trial-eligible because of the
absence of a LVEF measurement. Similarly, patients were
only considered MERIT-HF eligible when they were treated
with a diuretic and ACE-I (or angiotensin-II-antagonist) and
RALES-eligible when treated with an ACE-I and loop diuretic.
Overall, 1346 patients (13%) would have qualiﬁed for
participating in at least one of the three selected trials
(Table 2 ). Within this pooled trial-eligible population, 256
patients would have qualiﬁed for all three trials and 692
patients would have qualiﬁed for at least two trials. These
trial-eligible patients show considerable differences when
compared with those who did not qualify for trial partici-
pation. Consistent with the results of clinical trials, the
majority of trial-eligible patients were men (75%). It should
be noted, however, that almost half (47%) of the survey par-
ticipants were women, but they represented only 27% of
those with a LVEF 0.40. Ischaemic heart disease was
observed less frequently in patients without exclusion
criteria but unknown LVEF (other survey patients) when
compared with trial-eligible and trial-ineligible patients.
Limited life expectancywas deﬁned as any knownmalignancy
and observed in 16% of the trial-ineligible patients.
Most patients who fulﬁlled trial criteria were treated with
ACE-Is (83–100%) (Table 3 ). Almost two-third of all trial-
eligible patients were treated with at least half of the
target dose and 40–50% received the minimum regulatory
recommended dose.13 As the recommended maintenance
doses of ACE-Is in the guidelines are given as dose ranges,
we repeated the analysis using the maximum regulatory
recommended doses. This corresponded to 50% of SOLVD
and 57% of MERIT-HF and RALES eligible patients who were
treated with at least half of this higher target dose. With
regard to b-blockers, 54% of MERIT-eligible patients received
a b-blocker, of whom in 20% at least half of the target dose
was given, whereas only 6% received the target dose.
Aldosterone antagonists were given to a large minority
(43%) of heart failure patients, fulﬁlling the enrolment
criteria of the RALES trial. Of all survey patients, 3658
(34% of all patients or 54% of those who underwent
imaging) had evidence of a left ventricular systolic dysfunc-
tion (LVSD), deﬁned as a LVEF 0.40 or a report of moderate
or severe LVSD on echocardiography. Of these patients, 78%
was treated with an ACE-I, 46% with a b-blocker, and 29%
with an aldosterone antagonist. In the absence of renal
failure and asthma (n ¼ 2762, 26%), slightly more patients
were given ACE-Is (80%) and b-blocker (48%), whereas
treatment with aldosterone antagonists remained 29%.
The incidence of all-cause mortality during the 12-week
follow-up period of hospital survivors was lower in patients
who received at least 50% of the target dose of ACE-Is or
b-blockers in, respectively, SOLVD (4.0 vs. 8.7%) and
MERIT-HF (2.9 vs. 8.8%) eligible patients (Table 4 ). This ben-
eﬁcial effect of treating patients with 50% of the target
dose was also observed in patients who did not fulﬁl the
study criteria of the selected trials.
Discussion
The present study clearly revealed that the patients
enrolled in RCTs are a highly selected group. Only a small
proportion of patients enrolled in the Euro Heart Survey on
Heart Failure would have fulﬁlled the entry criteria of at
least one of the selected landmark trials. In this subgroup
of trial-eligible patients, hardly one-half were prescribed a
b-blocker and the doses of ACE-Is and b-blockers used
were lower than those proven to be effective in large
controlled clinical trials. Therefore, lack of similarity
between patients with heart failure in clinical practise and
those in clinical trials does not adequately explain under-
utilization of therapy.
It is in keeping with earlier reports that a minority of heart
failure patients in clinical practise would have qualiﬁed for
participation in landmark RCTs.21–27 It should be noted,
however, that the absence of a quantitative measurement
of the LV function and the failure to prescribe ACE-Is
excluded many patients from being considered trial eligible.
As only few patients fulﬁlled all clinical trial criteria, we
also tried to identify the maximum potential numbers of
patients who should receive an ACE-I and b-blocker
(i.e. those with evidence of LVEF, without contraindications
like renal failure or asthma). Treatment of these patients
compared with trial-eligible patients revealed only minor
differences with respect to ACE-Is and b-blockers. Aldo-
sterone antagonists, however, were given more frequently
in trial-eligible patients.
This analysis shows that the under-representation of
women in heart failure trials23,24 is partly explained by the
use of a low LVEF as an inclusion criterion and the higher
prevalence of preserved LVEF among women. To increase
the proportion of women in heart failure trials, it would
be necessary to introduce bias in favour of recruiting
women or relax the LVEF entry criterion. This analysis also
reveals that the exclusion of patients with preserved left
ventricular function (PLVF) and those with renal dysfunction
is an important reason for the average of patients in trials
being about a decade younger than the epidemiological
population.21–23 Indeed, in CHARM preserved,29 which
recruited only patients with PLVF, the proportion of women
was substantially higher and the patients somewhat older
than those in other RCTs of heart failure.
The limited generalizability of the results of RCTs is widely
recognized. Trials with more varied enrolment criteria are
required to provide information on the complete scope of
a disease and its treatment to extend generalizability. This
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Figure 1 Flow diagram illustrating the proportion of trial-eligible patients.
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Table 3 Patient characteristics and pharmacological treatment of trial-eligible patients enrolled in the EHS on Heart Failure
SOLVD-eligible MERIT-HF-eligible RALES-eligible Pooled RCTsa Trials
n 1005 507 782 8223 1–3
Age [median (25th–75th)] 65 (55–72) 67 (57–73) 68 (58–75) 63 1–3
Female gender (%) 224 (22) 141 (28) 179 (23) 1848 (22) 1–3
Non-excluding co-morbidity (%)
Hypertension 447 (45) 254 (50) 382 (49) 2835 (43) 2,3
Diabetes mellitus 262 (26) 140 (28) 207 (27) 1647 (25) 2,3
Chronic atrial ﬁbrillation 212 (21) 104 (21) 166 (21) 689 (14) 2,3
Prior myocardial infarction 463 (46) 229 (45) 409 (52) 3611 (55) 2,3
Prior coronary intervention 216 (22) 106 (21) 139 (18) — —
Pharmacological treatment (%)
ACE-Is
Treated 829 (83) 472 (93) 782 (100) 6714 (91) 1,3
50% of target dose 605 (60) 337 (67) 564 (72) — —
target dose 408 (41) 231 (46) 375 (48) — —
b-Blockers
Treated 489 (49) 272 (54) 357 (46) 371 (9) 1,2
50% of target dose 172 (17) 102 (20) 129 (17) — —
target dose 54 (5) 29 (6) 44 (6) — —
Cardiac glycosides
Treated 484 (48) 260 (51) 373 (48) 5479 (67) 1–3
Diuretics
Treated 900 (90) 507 (100) 782 (100) 7463 (91) 1–3
Aldosterone antagonists
Treated 418 (42) 213 (42) 334 (43) — —
For ACE-Is the daily target doses were deﬁned as 75 mg for captopril, 20 mg for enalapril, 5 mg for ramipril, 5 mg for lisinopril, and 4 mg for perindopril.
For b-blockers these doses were 150 mg for metoprolol, 50 mg for atenolol, 50 mg for carvedilol, and 10 mg for bisoprolol.
aData based on results as presented in the main articles of the three RCTs (1, SOLVD; 2, MERIT-HF; 3, RALES).
Table 2 Baseline characteristics of patients enrolled in the Euro Heart Survey on Heart Failure
Total Trial-eligible
(pooled)
Trial-ineligible
(pooled)
Other survey
patientsb
P-value
n 10701 1346a 6595 2760
Age [median (25th–75th)] 73 (64–80) 67 (57–74) 74 (64–82) 74 (66–79) ,0.001
Gender (women) (%) 5020 (47) 342 (25) 3207 (49) 1471 (53) ,0.001
Co-morbidity (%)
Hypertension 5679 (53) 636 (47) 3534 (54) 1509 (55) ,0.001
Diabetes mellitus 2907 (27) 355 (26) 1723 (26) 829 (30) ,0.001
Ischaemic heart disease 6419 (60) 841 (63) 4246 (64) 1332 (48) ,0.001
Acute coronary syndromea 2883 (27) 166 (12) 2505 (38) 212 (8) ,0.001
Valvular heart diseasea 768 (7) 41 (3) 677 (10) 50 (2) ,0.001
Renal insufﬁciencya,c 1163 (11) 82 (6) 974 (15) 107 (4) ,0.001
Pulmonary disease 2876 (27) 245 (18) 1701 (26) 930 (34) ,0.001
Severe pulmonary diseasea 1743 (16) 188 (14) 971 (15) 584 (21) ,0.001
Prior/current stroke 939 (9) 83 (6) 541 (8) 315 (11) ,0.001
Chronic atrial ﬁbrillation 2482 (23) 284 (21) 1520 (23) 678 (25) 0.04
Cancera 1058 (10) 0 (0) 1058 (16) 0 —
LVEF known (%) 5311 (50) 1346 (100) 3965 (60) 0 —
LVEF [median (25th–75th)]d 41 (30–55) 29 (22–33) 48 (40–60) — ,0.001
Pharmacological treatment (%)
ACE-Is 6610 (62) 1158 (86) 3595 (55) 1857 (67) ,0.001
b-Blockers 3744 (37) 650 (48) 2584 (39) 710 (26) ,0.001
Cardiac glycosides 3825 (36) 622 (46) 2147 (33) 1056 (38) ,0.001
Diuretics 9297 (87) 1241 (92) 5521 (84) 2535 (92) ,0.001
Aldosterone antagonists 2197 (21) 522 (39) 1135 (17) 540 (20) ,0.001
aMajor exclusion criteria of the selected trials, as shown in Table 1.
bPatients without major exclusion criteria, but without known LVEF.
cCreatinine 177 mmol/L or 2.0 mg/dL.
dOnly in patients with known LVEF.
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has happened with ACE-Is over the last 15 years. Trials in
post-infarction patients with LVSD and in patients with vas-
cular disease without heart failure suggest that the beneﬁts
of ACE-Is may be generalizable, although no trials have
shown morbidity or mortality beneﬁt in patients with PLVF
as yet. ACE-Is have a well-recognized side-effect proﬁle
and are well tolerated.30 Similarly, trials of b-blockers
have shown beneﬁt in patients with heart failure and LVSD
and in patients who have had a myocardial infarction. The
SENIORS31 and a smaller study of propranolol32 suggest
that b-blockers are effective even in elderly patients,
regardless of the LVEF. A recent analysis of patients in this
survey revealed that patients treated with ACE-Is or
b-blockers, irrespective of the LVEF, had a better survival
than those who did not.33
Treatment with aldosterone antagonists is based on only
two clinical trials, RALES and EPHESUS,9,10 and more RCTs
are desirable to increase generalizability. Achieving the
equipoise between the ethics of withholding a treatment
that has shown striking reductions in mortality against the
desire to demonstrate generalizability may be difﬁcult but
important to demonstrate safety and efﬁcacy in wider
clinical practise.34,35
Although adherence to guidelines is encouraged by
national and international societies, not all patients will or
should be treated as advocated in the guidelines. Guidelines
only provide the general principle of how a patient should be
treated; they do not address every individual patient’s clini-
cal problem. Management of individual patients is more
complex than simply following the guidelines, as contraindi-
cations, individual reactions to the medication side-effects,
co-morbidity, and subsequent multiple co-medications as
well as the treatment goals for the individual patient can
affect management decisions.27,36 However, this survey
suggests that there is a shortfall in effective therapy, even
when patients in clinical practise fulﬁl the criteria of land-
mark clinical trials of heart failure treatment.
These observations raise the question why a sizable
proportion of patients were not treated according to
evidence-based guidelines. Identiﬁed barriers in following
clinical guidelines, such as lack of awareness, lack of agree-
ment with the guidelines, difﬁcult to use (not concise
enough), no motivation to change current practise, as well
as economic pressure to limit the costs, and so on, might
partly explain the limited adherence to guidelines in clinical
practise.29,30,37 These barriers imply that more effort is
needed to improve guideline adherence. It is acknowledged
that initiation and up-titration of these drugs require
careful, repeated assessment to monitor individual
responses. Especially in the case of b-blockers, treatment
can provoke initial worsening. Concerns that initiation of a
b-blocker too early during hospitalization could destabilize
the patient38 should also be taken into account when
trying to explain why physicians were unable to initiate
evidence-based therapy. Regarding up-titration of ACE-Is and
b-blockers, it should be noted that this requires an effective
heart failure follow-up program, as it is to be expected that
the majority of patients are not hospitalized during this
phase. Conversely, some have advocated that ﬁxed target
doses may not be optimal for individual patients.18 In
addition to this, doctors may be satisﬁed with a sympto-
matic improvement already with smaller doses of drugs
and not push for higher targets to avoid adverse events.
Thus, smaller doses than recommended can and should not
generally be regarded as suboptimal therapy. In our
survey, however, the underlying reason for choosing dosage
cannot be reliably analysed. The clinical trial evidence indi-
cating that target doses of ACE-Is and b-blockers are more
effective than lower doses is sparse. Randomized controlled
trials do suggest that higher doses of ACE-Is may be more
effective.39–41 There is less evidence that the dose of
b-blocker is important.42,43 However, a beneﬁcial effect in
patients who were treated with at least 50% of the doses
used in RCTs, compared with patients who received less,
was observed in this survey. It should be noted, however,
that most of the evidence for beneﬁt is based on titration
to target doses recommended by landmark trials.
Limitations
As most hospitals volunteered, it is possible that the
observed pharmacological treatment was even better than
in every day clinical practise, because they were energetic
in implementing existing evidence. In selecting trial-eligible
patients, we focused on the most important entry criteria
for the trials but did not include every detail. Finally, it is
possible that some of the under-utilization of b-blockers
reﬂects the fact that the patients had recently been
hospitalized. At the time of the survey, it was generally
recommended to stabilize patients ﬁrst, before initiating
b-blockers.
Conclusion
Only a minority of patients with heart failure would be
eligible for participation in the majority of randomized
controlled trials of heart failure. This reﬂects the general
exclusion of patients with PLVF and, to a lesser extent,
Table 4 Twelve-week mortality of hospital survivors in relation to target doses
Subpopulation Treatment Target dose (%) n Follow-up mortality P-value
SOLVD-eligible ACE-Is 50 600 24 (4.0) 0.002
,50 379 33 (8.7)
MERIT-HF-eligible b-Blockers 50 102 3 (2.9) 0.04
,50 399 35 (8.8)
Trial-ineligible (pooled) ACE-Is 50 2367 102 (4.3) ,0.001
,50 3671 317 (8.6)
b-Blockers 50 1224 47 (3.8) ,0.001
,50 4814 372 (7.7)
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renal dysfunction. Among patients who fulﬁlled the key
enrolment criteria of selected landmark trials, ACE-Is,
b-blockers, and aldosterone antagonists were under-
utilized. This survey, however, gave no clues for the reason
of under-utilization.
Conﬂict of interest: no conﬂict of interest with respect to this
manuscript.
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